home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
Shareware Overload Trio 2
/
Shareware Overload Trio Volume 2 (Chestnut CD-ROM).ISO
/
dir26
/
med9410b.zip
/
M94A0259.TXT
< prev
next >
Wrap
Text File
|
1994-10-08
|
2KB
|
39 lines
Document 0259
DOCN M94A0259
TI Treatment with intravenous
(S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]-cytosine of
acyclovir-resistant mucocutaneous infection with herpes simplex virus in
a patient with AIDS.
DT 9412
AU Lalezari JP; Drew WL; Glutzer E; Miner D; Safrin S; Owen WF Jr; Davidson
JM; Fisher PE; Jaffe HS; Mount Zion Medical Center, University of
California, San; Francisco.
SO J Infect Dis. 1994 Sep;170(3):570-2. Unique Identifier : AIDSLINE
MED/94358489
AB (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine (HPMPC) is a
nucleotide analogue with potent in vitro and in vivo activity against a
broad range of herpesviruses, including acyclovir-resistant herpes
simplex virus (HSV). A patient with severe acyclovir-resistant perineal
HSV infection received intravenous HPMPC at 5 mg/kg/week, with
concomitant oral probenecid and prehydration, and had 95% healing after
four infusions. The patient developed a hypersensitivity reaction to
probenecid and discontinued HPMPC after the fourth infusion. Recurrence
of the perineal lesions 2 weeks later prompted initiation of an oral
desensitization program to probenecid and enabled the patient to resume
therapy. The lesions again responded to infusions of HPMPC, but the drug
was discontinued before complete healing because of transient
nephrotoxicity (proteinuria, 2+; creatinine, 1.7 mg/dL). HPMPC is a
potent antiviral agent that holds promise as a potential treatment for
acyclovir-resistant HSV infection.
DE Acyclovir/*THERAPEUTIC USE Antiviral Agents/*THERAPEUTIC USE
AIDS-Related Opportunistic Infections/*DRUG THERAPY Case Report
Cytosine/*ANALOGS & DERIVATIVES/THERAPEUTIC USE Drug Resistance,
Microbial Herpes Simplex/*DRUG THERAPY Human Male Microbial
Sensitivity Tests Middle Age Organophosphorus Compounds/*THERAPEUTIC
USE Simplexvirus/DRUG EFFECTS Support, Non-U.S. Gov't Support, U.S.
Gov't, P.H.S. JOURNAL ARTICLE
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).